The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1290
July 14, 2008
View Complete Issue         Table of Contents 2019 
Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation
July 14, 2008 (Issue: 1290)
Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation
Article code: 1290b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.